Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept

Adam Mor, Clifton O. Bingham, Laura Barisoni, Eileen Lydon, H. Michael Belmont

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine. Agents that neutralize TNF-α are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-α antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leuko-cytoclastic vasculitis in a patient treated with etanercept for JRA.

Original languageEnglish (US)
Pages (from-to)740-743
Number of pages4
JournalJournal of Rheumatology
Issue number4
StatePublished - Apr 1 2005
Externally publishedYes


  • Etanercept
  • Nephritis
  • Systemic lupus erythematosus
  • Tumor necrosis factor
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept'. Together they form a unique fingerprint.

Cite this